Pui Y Lee1, Erinn S Kellner2, Yuelong Huang3, Elissa Furutani4, Zhengping Huang5, Wayne Bainter6, Mohammed F Alosaimi7, Kelsey Stafstrom6, Craig D Platt6, Tali Stauber8, Somech Raz8, Irit Tirosh9, Aaron Weiss10, Michael B Jordan11, Christa Krupski12, Despina Eleftheriou13, Paul Brogan13, Ali Sobh14, Zeina Baz15, Gerard Lefranc16, Carla Irani17, Sara S Kilic18, Rasha El-Owaidy19, M R Lokeshwar20, Pallavi Pimpale21, Raju Khubchandani21, Eugene P Chambers22, Janet Chou6, Raif S Geha6, Peter A Nigrovic23, Qing Zhou24. 1. Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. Electronic address: pui.lee@childrens.harvard.edu. 2. Division of Allergy/Immunology, Cincinnati Children's Hospital and University of Cincinnati, Cincinnati, Ohio. 3. Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. 4. Dana Farber and Boston Children's Cancer and Blood Disorders Center, Boston, Mass. 5. Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass; Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China. 6. Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass. 7. Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass; Department of Pediatrics, King Saud University, Riyadh, Saudi Arabia. 8. Primary Immunodeficiency Clinic, Sheba Medical Center, Jeffrey Modell Foundation, Tel Hashomer, Israel. 9. Pediatric Rheumatology Service, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel. 10. Department of Pediatrics, Maine Medical Center, Portland, Me. 11. Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio; Division of Immunobiology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio. 12. Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio. 13. University College London, Great Ormond Street Institute of Child Health, London, United Kingdom. 14. Department of Pediatrics, Mansoura University Children's Hospital, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 15. Department of Pediatrics, St George Hospital University Medical Center, Beirut, Lebanon. 16. Institut de Génétique Humaine, UMR 9002 CNRS-Université de Montpellier, Montpellier, France. 17. Internal Medicine & Clinical Immunology Department, Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon. 18. Department of Pediatric Immunology and Rheumatology, Uludag University Medical Faculty, Bursa, Turkey. 19. Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt. 20. Department of Pediatrics, Lilavati Hospital and Research Centre, Mumbai, India. 21. SRCC Children's Hospital, Mumbai, India. 22. Department of Surgery, Vanderbilt University Medical Center, Nashville, Tenn; DADA2 Foundation, Nashville, Tenn. 23. Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. 24. Life Sciences Institute, Zhejiang University, Zhejiang, China.
Abstract
BACKGROUND: Deficiency of adenosine deaminase 2 (DADA2) is a syndrome with pleiotropic manifestations including vasculitis and hematologic compromise. A systematic definition of the relationship between adenosine deaminase 2 (ADA2) mutations and clinical phenotype remains unavailable. OBJECTIVE: We sought to test whether the impact of ADA2 mutations on enzyme function correlates with clinical presentation. METHODS: Patients with DADA2 with severe hematologic manifestations were compared with vasculitis-predominant patients. Enzymatic activity was assessed using expression constructs reflecting all 53 missense, nonsense, insertion, and deletion genotypes from 152 patients across the DADA2 spectrum. RESULTS: We identified patients with DADA2 presenting with pure red cell aplasia (n = 5) or bone marrow failure (BMF, n = 10) syndrome. Most patients did not exhibit features of vasculitis. Recurrent infection, hepatosplenomegaly, and gingivitis were common in patients with BMF, of whom half died from infection. Unlike patients with DADA2 with vasculitis, patients with pure red cell aplasia and BMF proved largely refractory to TNF inhibitors. ADA2 variants associated with vasculitis predominantly reflected missense mutations with at least 3% residual enzymatic activity. In contrast, pure red cell aplasia and BMF were associated with missense mutations with minimal residual enzyme activity, nonsense variants, and insertions/deletions resulting in complete loss of function. CONCLUSIONS: Functional interrogation of ADA2 mutations reveals an association of subtotal function loss with vasculitis, typically responsive to TNF blockade, whereas more extensive loss is observed in hematologic disease, which may be refractory to treatment. These findings establish a genotype-phenotype spectrum in DADA2.
BACKGROUND: Deficiency of adenosine deaminase 2 (DADA2) is a syndrome with pleiotropic manifestations including vasculitis and hematologic compromise. A systematic definition of the relationship between adenosine deaminase 2 (ADA2) mutations and clinical phenotype remains unavailable. OBJECTIVE: We sought to test whether the impact of ADA2 mutations on enzyme function correlates with clinical presentation. METHODS:Patients with DADA2 with severe hematologic manifestations were compared with vasculitis-predominant patients. Enzymatic activity was assessed using expression constructs reflecting all 53 missense, nonsense, insertion, and deletion genotypes from 152 patients across the DADA2 spectrum. RESULTS: We identified patients with DADA2 presenting with pure red cell aplasia (n = 5) or bone marrow failure (BMF, n = 10) syndrome. Most patients did not exhibit features of vasculitis. Recurrent infection, hepatosplenomegaly, and gingivitis were common in patients with BMF, of whom half died from infection. Unlike patients with DADA2 with vasculitis, patients with pure red cell aplasia and BMF proved largely refractory to TNF inhibitors. ADA2 variants associated with vasculitis predominantly reflected missense mutations with at least 3% residual enzymatic activity. In contrast, pure red cell aplasia and BMF were associated with missense mutations with minimal residual enzyme activity, nonsense variants, and insertions/deletions resulting in complete loss of function. CONCLUSIONS: Functional interrogation of ADA2 mutations reveals an association of subtotal function loss with vasculitis, typically responsive to TNF blockade, whereas more extensive loss is observed in hematologic disease, which may be refractory to treatment. These findings establish a genotype-phenotype spectrum in DADA2.
Authors: Rohit R Ghurye; Kruthika Sundaram; Frances Smith; Barnaby Clark; Michael A Simpson; Lynette Fairbanks; Zoe Adhya; Ghulam J Mufti; Judith C W Marsh; Mohammad A A Ibrahim Journal: Br J Haematol Date: 2019-03-28 Impact factor: 6.998
Authors: Johanna Schepp; Michele Proietti; Natalie Frede; Mary Buchta; Katrin Hübscher; Jessica Rojas Restrepo; Sigune Goldacker; Klaus Warnatz; Jana Pachlopnik Schmid; Andrea Duppenthaler; Vassilios Lougaris; Ignacio Uriarte; Susan Kelly; Michael Hershfield; Bodo Grimbacher Journal: Arthritis Rheumatol Date: 2017-07-05 Impact factor: 10.995
Authors: Amanda K Ombrello; Jing Qin; Patrycja M Hoffmann; Parag Kumar; Deborah Stone; Anne Jones; Tina Romeo; Beverly Barham; Gineth Pinto-Patarroyo; Camilo Toro; Ariane Soldatos; Qing Zhou; Natalie Deuitch; Ivona Aksentijevich; Sherry L Sheldon; Susan Kelly; Ada Man; Karyl Barron; Michael Hershfield; Willy A Flegel; Daniel L Kastner Journal: N Engl J Med Date: 2019-04-18 Impact factor: 91.245
Authors: Paulina Navon Elkan; Sarah B Pierce; Reeval Segel; Tom Walsh; Judith Barash; Shai Padeh; Abraham Zlotogorski; Yackov Berkun; Joseph J Press; Masha Mukamel; Isabel Voth; Philip J Hashkes; Liora Harel; Vered Hoffer; Eduard Ling; Fatos Yalcinkaya; Ozgur Kasapcopur; Ming K Lee; Rachel E Klevit; Paul Renbaum; Ariella Weinberg-Shukron; Elif F Sener; Barbara Schormair; Sharon Zeligson; Dina Marek-Yagel; Tim M Strom; Mordechai Shohat; Amihood Singer; Alan Rubinow; Elon Pras; Juliane Winkelmann; Mustafa Tekin; Yair Anikster; Mary-Claire King; Ephrat Levy-Lahad Journal: N Engl J Med Date: 2014-02-19 Impact factor: 91.245
Authors: Amy P Hsu; Robert R West; Katherine R Calvo; Jennifer Cuellar-Rodriguez; Mark Parta; Susan J Kelly; Nancy J Ganson; Michael S Hershfield; Steven M Holland; Dennis D Hickstein Journal: J Allergy Clin Immunol Date: 2016-04-06 Impact factor: 10.793
Authors: Pui Y Lee; Yuelong Huang; Qing Zhou; Oskar Schnappauf; Michael S Hershfield; Ying Li; Nancy J Ganson; Natalia Sampaio Moura; Ottavia M Delmonte; Scellig S Stone; Michael J Rivkin; Sung-Yun Pai; Todd Lyons; Robert P Sundel; Victor W Hsu; Luigi D Notarangelo; Ivona Aksentijevich; Peter A Nigrovic Journal: J Allergy Clin Immunol Date: 2018-06-21 Impact factor: 10.793
Authors: Katrijn Arts; Jenna R E Bergerson; Amanda K Ombrello; Morgan Similuk; Andrew J Oler; Anahita Agharahimi; Emily M Mace; Mike Hershfield; Carine Wouters; Lien De Somer; Marie-Anne Morren; Rebeca Perez-de Diego; Leen Moens; Alexandra F Freeman; Isabelle Meyts Journal: J Clin Immunol Date: 2018-11-01 Impact factor: 8.542
Authors: Oskar Schnappauf; Qing Zhou; Natalia Sampaio Moura; Amanda K Ombrello; Drew G Michael; Natalie Deuitch; Karyl Barron; Deborah L Stone; Patrycja Hoffmann; Michael Hershfield; Carolyn Applegate; Hans T Bjornsson; David B Beck; P Dane Witmer; Nara Sobreira; Elizabeth Wohler; John A Chiorini; The American Genome Center; Clifton L Dalgard; Nih Intramural Sequencing Center; Daniel L Kastner; Ivona Aksentijevich Journal: J Clin Immunol Date: 2020-07-08 Impact factor: 8.317
Authors: A F Geraldo; R Caorsi; D Tortora; C Gandolfo; R Ammendola; M Alessio; G Conti; A Insalaco; S Pastore; S Martino; I Ceccherini; S Signa; M Gattorno; A Rossi; M Severino Journal: AJNR Am J Neuroradiol Date: 2021-02-25 Impact factor: 3.825
Authors: Hyuk Jee; Zhengping Huang; Samantha Baxter; Yuelong Huang; Maria L Taylor; Lauren A Henderson; Sofia Rosenzweig; Aman Sharma; Eugene P Chambers; Michael S Hershfield; Qing Zhou; Fatma Dedeoglu; Ivona Aksentijevich; Peter A Nigrovic; Anne O'Donnell-Luria; Pui Y Lee Journal: J Allergy Clin Immunol Date: 2021-05-15 Impact factor: 10.793
Authors: Oludare A Odumade; Alec L Plotkin; Jensen Pak; Olubukola T Idoko; Matthew A Pettengill; Tobias R Kollmann; Al Ozonoff; Beate Kampmann; Ofer Levy; Kinga K Smolen Journal: Front Immunol Date: 2021-05-27 Impact factor: 7.561